We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
Cap. Flow
-$415M
Cap. Flow %
-21.46%
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$87.5M
2
SPTX
Seaport Therapeutics
SPTX
+$62.7M
3
GILD icon
Gilead Sciences
GILD
+$45.2M
4
ANAB icon
AnaptysBio
ANAB
+$14.9M
5
ABT icon
Abbott
ABT
+$11.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$89.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$63.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$51M
4
UTHR icon
United Therapeutics
UTHR
+$47.1M
5
BIIB icon
Biogen
BIIB
+$42.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.78%
2 Miscellaneous 3.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47.4B
$421M 21.76%
1,550,280
– –
VERA icon
2
Vera Therapeutics
VERA
$2.5B
$120M 6.2%
2,793,987
– –
GMAB icon
3
Genmab
GMAB
$20B
$111M 5.74%
4,045,215
+3,292,954
+438% +$87.5M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$88M 4.55%
365,341
-232,986
-39% -$51M
RAPP
5
Rapport Therapeutics
RAPP
$2.09B
$79.4M 4.1%
1,904,408
– –
SPTX
6
Seaport Therapeutics
SPTX
$1.28B
$77.4M 4%
+3,564,871
New +$62.7M
AVBP icon
7
ArriVent BioPharma
AVBP
$1.42B
$58.9M 3.05%
1,696,752
– –
RARE icon
8
Ultragenyx Pharmaceutical
RARE
$1.42B
$57.3M 2.96%
1,717,505
-1,428,383
-45% -$35.5M
BIOA
9
BioAge Labs
BIOA
$386M
$56.2M 2.91%
2,293,788
– –
BMY icon
10
Bristol-Myers Squibb
BMY
$130B
$50.5M 2.61%
876,970
-1,111,751
-56% -$63.8M
SUPN icon
11
Supernus Pharmaceuticals
SUPN
$2.44B
$48.2M 2.49%
1,036,328
+82,019
+9% +$3.94M
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7.27B
$45.3M 2.34%
408,027
-42,069
-9% -$3.8M
GILD icon
13
Gilead Sciences
GILD
$179B
$43.3M 2.24%
+343,100
New +$45.2M
UTHR icon
14
United Therapeutics
UTHR
$21.4B
$41.4M 2.14%
76,489
-83,581
-52% -$47.1M
COGT icon
15
Cogent Biosciences
COGT
$5.78B
$40.1M 2.07%
1,035,148
-1,078,403
-51% -$37.7M
AXSM icon
16
Axsome Therapeutics
AXSM
$11.6B
$39.3M 2.03%
160,429
-52,318
-25% -$11.3M
IMTX icon
17
Immatics
IMTX
$1.34B
$37.2M 1.92%
3,669,346
+38,892
+1% +$411K
DYN icon
18
Dyne Therapeutics
DYN
$3.36B
$36.8M 1.9%
1,658,384
+24,487
+1% +$455K
IMNM icon
19
Immunome
IMNM
$2.84B
$36.5M 1.88%
1,720,316
+18,412
+1% +$394K
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.65B
$34.5M 1.78%
925,119
-206,667
-18% -$6.33M
ANAB icon
21
AnaptysBio
ANAB
$1.62B
$33.3M 1.72%
493,536
+245,283
+99% +$14.9M
NKTR icon
22
Nektar Therapeutics
NKTR
$2.37B
$32.9M 1.7%
471,763
-37,783
-7% -$2.76M
PHVS icon
23
Pharvaris
PHVS
$2.71B
$30.5M 1.58%
881,299
+62,971
+8% +$1.91M
RCUS icon
24
Arcus Biosciences
RCUS
$3.12B
$29.2M 1.51%
945,690
+22,604
+2% +$559K
INBX icon
25
Inhibrx
INBX
$1.62B
$28.7M 1.48%
303,103
-102,926
-25% -$10.3M
1
2 3 4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.

  • Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
  • Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
  • Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
  • Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
  • Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.